Autoimmune thyroid diseases (AITDs) are archetypes of organ-specific diseases, where disease phenotypes seem to derive from the interaction of genetic and environmental factors. AITDs mainly consist of Graves' disease (GD) and Hashimoto's thyroiditis (HT). It is known that genetic factors play an important role in the development of AITDs. A number of twin studies show approximately 75% of the total phenotypic variance in AITDs is because of genetic effects ([@bib3]). AITDs genetic etiology is well established but the main genetic variants and their epistasis still need to be uncovered. Specific genes and alleles are necessary, such as human leukocyte antigen (HLA) ([@bib2]; [@bib16]), cytotoxic T lymphocyte-associated antigen (CTLA-4) ([@bib11]), protein tyrosine phosphatase-22 (PTPN22) ([@bib8]), and thyroid-stimulating hormone receptor gene (TSHR) ([@bib20]; [@bib12]) but they are not sufficient for disease development. In order to identify additional risk variants, we examined the distribution of the allele and genotypes of CLEC16A gene in AITDs patients.

CLEC16A (C-type lectin domain 16, previously known as KIAA0350) is located in a 233-kb linkage disequilibrium block on chromosome 16p13. CLEC16A is a protein in humans that is encoded by the CLEC16A gene. It is a member of the C type lectin family. Members of this family are thought to provide an important signal for immune tolerance ([@bib6]). However, this protein lacks crucial domains in carbohydrate recognition, which can be involved in diverse processes, including plasma glycoprotein turnover, cell--cell adhesion, and innate pathogen recognition. Until now, little is known about the detailed function of this protein, despite it being highly expressed on B-lymphocytes, natural killer (NK) and dendritic cells (DC) ([@bib17]).

Up to now, a number of studies showed significant associations of CLEC16A gene with autoimmune diseases such as type 1 diabetes ([@bib4]; [@bib15]), multiple sclerosis ([@bib9]; [@bib21]), and juvenile idiopathic arthritis ([@bib18]). To better understand the role of CLEC16A as an autoimmune risk locus and the association between CLEC16A and AITDs, this research was performed.

Materials and Methods {#s1}
=====================

Experimental subjects {#s2}
---------------------

All AITDs (GD and HT) patients and controls in the present case-control study were Chinese Han population. They were recruited in the endocrinology outpatient department of First Affiliated Hospital of Xi'an Jiaotong University. The research project was approved by the ethics committee of the hospital. We investigated 667 non-related AITDs patients consisting of 417 GD patients (124 males and 293 females; ages 5--73 years 34.48 ± 13.95 years) and 250 HT patients (39 males and 211 females; ages 4--77 years, 31.90 ± 13.10 years). The detailed information of the subjects was shown in [Table 1](#t1){ref-type="table"}. The diagnostic criteria for AITDs were based on our previous published paper ([@bib12]). GD patients were diagnosed by clinical manifestations and biochemical assessments of hyperthyroidism and the positive circulating thyroid-stimulating hormone receptor antibody (TRAb), with or without positive antibody against thyroid peroxidase (TPOAb) or antibody against thyroglobulin (TGAb) and diffuse goiter of the thyroid. HT was defined based on the high level of either TPOAb or TGAb, with or without clinical and biochemical hypothyroidism and the presence of an enlarged thyroid. And 301 healthy subjects (91 males and 210 females; ages 10--72 years, 33.60 ±12.64 years) without clinical evidence (goiter, TPOAb, and TGAb) and family history of any autoimmune diseases were selected from the health care center of the same hospital and were used as controls.

###### Clinical data of AITDs patients and controls

                   GD              HT              Control
  ---------------- --------------- --------------- ---------------
  N                417             250             301
  Sex                                              
   Male            124 (29.74%)    39 (15.60%)     91 (30.23)
   Female          293 (70.26%)    211 (84.40%)    210 (69.77%)
  Age              34.48 ± 13.95   31.90 ± 13.10   33.60 ± 12.64
  Onset of age     32.31 ± 14.07   30.29 ± 13.05   
  Thyroid size                                     
   Normal          55 (13.19%)     21 (8.40%)      
   First degree    65 (15.59%)     37 (14.80%)     
   Second degree   231 (55.39%)    169 (67.60%)    
   Third degree    66 (15.83%)     23 (9.20%)      
  Family history                                   
   (+)             72 (17.27%)     54 (21.60%)     
   (−)             345 (82.73)     196 (78.40%)    
  Ophthalmopathy                                   
   (+)             98 (23.50%)     6 (2.40%)       
   (−)             319 (76.50%)    244 (97.60%)    

AITDs, autoimmune thyroid diseases; GD, Graves' disease; HT, Hashimoto's thyroiditis.

Genotyping {#s3}
----------

1−2 mL peripheral venous blood was collected from all subjects. The genomic DNA was extracted from the blood by using RelaxGene Blood DNA System (Tiangen Biotech, Beijing, China). Marker-tagging single-nucleotide polymorphisms (SNPs) were selected from the Hapmap CHB data using the Haploview software to meet the following criteria: minor allele frequency \>0.1 and Hardy-Weinberg equilibrium (HWE) with *P* \> 0.001. rs12708716, rs12917716, rs12931878, rs290369, and rs6498169 SNPs were typed by a matrix-assisted laser desorption ionization-time of flight mass spectrometer (MALDI-TOF-MS) platform from Sequenom (San Diego, CA). Primer sequences for the targeted loci are as follows.

rs12708716 Forward: ACGTTGGATGACTTCATCCTCACTGACTCC

Reverse: ACGTTGGATGTCTCGGGTCTTCAGCTAGTC

rs12917716 Forward: ACGTTGGATGGCTTTTAGAGCAAGAACCAG

Reverse: ACGTTGGATGCTGCTATGAGGGCCTTTCCA

rs12931878 Forward: ACGTTGGATGCAGAGACCACAGGTATGAAG

Reverse: ACGTTGGATGAACACTCCCAGCTTGCAAAC

rs2903692 Forward: ACGTTGGATGCTAGGTCTGGTACAAAAGTG

Reverse: ACGTTGGATGTGGGAAATGGGTTCTGGATG

rs6498169 Forward: ACGTTGGATGTGTGGGACATGGCTAACCG

Reverse: ACGTTGGATGCTAAAGCCAAGTTGCTGCTC

Statistical analysis {#s4}
--------------------

The clinical data were described as mean± SD (mean ± standard deviation). Allele and genotype frequencies between cases and controls were compared using the chi-square test. The odds ratio (OR) and 95% confidence interval (95% CI) were calculated. All statistical analyses were performed using the software SPSS, version 16.0. And *P* \< 0.05 was considered as statistically significant. Haplotypes for SNPs were tested for Hardy-Weinberg equilibrium using Haploview 4.0 analysis platform. Some investigators use multiple tests to examine multiple candidate cut-points and adjust their *P* values. All *P* values presented in this study were uncorrected.

Clinical phenotype analysis {#s5}
---------------------------

Clinical data of AITDs patients and control groups were analyzed in the following ways: Clinical manifestations at the time of recruitment was divided into five parts: (1) gender: the number of male and female patients; (2) age of onset: (data are expressed as mean ± SD); (3) thyroid size: the size is divided into three degrees by palpation: first degree, the goiter cannot be seen but can be palpated; second degree, the goiter can be seen and palpated, but within the sternocleidomastoid; third degree, the goiter exceeds the exterior margin of sternocleidomastoid; (4) family history: the incidence of a disease of the patient's first and second degree family members; (5) ophthalmopathy, defined as distinctive disorder characterized by inflammation and swelling of the extraocular muscles, eyelid retraction, periorbital edema, episcleral vascular injection, conjunctival swelling, and proptosis.

Results {#s6}
=======

Allele and genotyping results {#s7}
-----------------------------

For rs6498169, the G allele was significantly more frequent in patients with AITDs (*P* = 0.029, OR 1.29, 95% CI 1.022−1.505) specifically in patients with HT (*P* = 0.018, OR 1.335, 95% CI 1.051−1.696) than in controls, but no association of this allele and GD was observed. Furthermore, we did not find any significant difference between patients and controls in all the other four SNPs (results shown in [Table 2](#t2){ref-type="table"}).

###### Allele distribution of CLEC16A gene in patients with AITDs

  SNP Name     Allele/Genotype   Control (%)   AITD (%)       *P* Value   GD (%)        *P* Value   HT (%)        *P* Value
  ------------ ----------------- ------------- -------------- ----------- ------------- ----------- ------------- -----------
  rs12708716   A                 451 (74.92)   1016 (76.16)   .554        633 (75.90)   .669        383 (76.60)   .517
               G                 151 (25.08)   318 (23.84)                201 (24.10)               117 (23.40)   
  rs12917716   C                 244 (40.53)   504 (38.24)    .339        312 (37.77)   .291        192 (39.02)   .612
               G                 358 (59.47)   814 (61.76)                514 (62.23)               300 (60.98)   
  rs12931878   A                 516 (86.0)    1167 (87.48)   .370        727 (87.17)   .52         440 (88.00)   .327
               G                 84 (14.0)     167 (12.52)                107 (12.83)               60 (12.00)    
  rs2903692    A                 156 (25.91)   303 (22.71)    .125        192 (23.02)   .207        111 (22.20)   .152
               G                 446 (74.09)   1031 (77.29)               642 (76.98)               389 (77.80)   
  rs6498169    A                 290 (48.33)   571 (43.0)     .029        365 (44.08)   .112        206 (41.20)   .018
               G                 310 (51.67)   757 (57.0)                 463 (55.92)               294 (58.80)   

AITDs, autoimmune thyroid diseases.

[Table 3](#t3){ref-type="table"} shows genotype distributions of rs12708716, rs12917716, rs12931878, rs2903692, and rs6498169 in patients with AITDs and controls. rs6498169 showed a marginally significant trend between HT subjects and control group under codominant model (*P* = 0.058), dominant model (*P* = 0.054) and under recessive model (*P* = 0.050). The GG genotype was higher in patients with HT, which indicates that the GG genotype could increase the susceptibility to HT. We failed to detect the genotype of few patients, both in rs12917716 and rs6498169, and these patients were excluded from the statistical analysis.

###### Genotype of the CECL16A SNPs in patients with GD and HT and controls

  SNP          Genotype   Control (%)   GD (%)        GD *vs.* Controls (*P*)   HT (%)   HT *vs.* Controls (P)                                 
  ------------ ---------- ------------- ------------- ------------------------- -------- ----------------------- ------------- ------- ------- -------
  rs12708716   AA         167 (55.48)   243 (58.27)   0.590                     0.456    0.648                   148 (59.20)   0.616   0.380   0.860
               AG         17 (5.65)     27 (6.47)                                                                15 (6.00)                     
               GG         117 (38.87)   147 (35.25)                                                              87 (34.80)                    
  rs12917716   CC         48 (15.95)    66 (15.98)    0.274                     0.990    0.131                   41 (16.67)    0.569   0.820   0.367
               CG         105 (34.88)   167 (40.44)                                                              95 (38.62)                    
               GG         148 (49.17)   180 (43.58)                                                              110 (44.72)                   
  rs12931878   AA         222 (74.00)   317 (76.02)   0.814                     0.537    0.750                   193 (77.20)   0.584   0.385   0.462
               AG         6 (2.00)      7 (1.68)                                                                 3 (1.20)                      
               GG         72 (24.00)    93 (22.30)                                                               54 (21.60)                    
  rs2903692    AA         19 (6.31)     26 (6.24)     0.282                     0.966    0.127                   15 (6.00)     0.227   0.879   0.092
               AG         164 (54.49)   251 (60.19)                                                              154 (61.60)                   
               GG         118 (39.20)   140 (33.57)                                                              81 (32.40)                    
  rs6498169    AA         69 (23.00)    83 (20.05)    0.251                     0.342    0.109                   41 (16.40)    0.058   0.054   0.050
               AG         79 (26.33)    132 (31.88)                                                              85 (34.00)                    
               GG         152 (50.67)   199 (48.07)                                                              124 (49.60)                   

SNP, single-nucleotide polymorphism; GD, Graves' disease; HT, Hashimoto's thyroiditis.

Genotype, allele distribution, and clinical phenotype association in AITDs patients {#s8}
-----------------------------------------------------------------------------------

Patients with AITDs were divided into family history-positive and family history-negative, and genotype and allele distribution were compared in all the five SNPs; unfortunately, no significant association was observed. The patients were also grouped according to the size of the thyroid, that is, those with third degree compared with those with first and second degree. The results also were not significant (data not shown).

Haplotype analysis {#s9}
------------------

[Table 4](#t4){ref-type="table"} shows the frequency of the GG haplotype in HT patient group was significantly higher than that in control group (*P* = 0.015, OR 1.344). It implies that GG was the risk haplotype to HT. However, the haplotypes of block 1 were neither associated with GD nor HT. Two detected LD blocks are shown in [Figure 1](#fig1){ref-type="fig"}, rs12908716-rs12917716 and rs2903692-rs6498169, according to D′ value.

###### Haplotype analysis in AITDs patients and controls

  Haplotype   Control (Frequency)   GD (Frequency)   *P*     OR   95%CI   HT (Frequency)   *P*      OR      95% CI
  ----------- --------------------- ---------------- ------- ---- ------- ---------------- -------- ------- -------------
  Block1                                                                                                    
   AG         355 (0.593)           43 (0.597))      0.928                303 (0.607)      0.658            
   GC         150 (0.250)           18 (0.250)       1                    115 (0.230)      0.44             
   AC         94 (0.157)            11 (0.153)       0.932                81 (0.162)       0.821            
  Block2                                                                                                    
   GG         309 (0.515)           42 (0.583)       0.273                294 (0.588)      0.0148   1.344   1.058−1.708
   AA         156 (0.260)           16 (0.222)       0.488                111 (0.222)      0.143            
   GA         135 (0.225)           14 (0.194)       0.555                95 (0.190)       0.155            

AITDs, autoimmune thyroid diseases; GD, Graves' disease; HT, Hashimoto's thyroiditis; OR, odds ratio; CI, confidence interval.

![Linkage disequilibrium (LD) block defined by the Haploview 4.1.](973f1){#fig1}

Discussion {#s10}
==========

CLEC16A gene is considered as a potential causal gene because it may encode an immunoreceptor tyrosine-based activation motif (ITAM), which can trigger properties of B-cell receptor (BCR), T-cell receptor (TCR), and Fc receptor (FcR) ([@bib7]). There are several SNPs in the CLEC16A gene linked with many autoimmune diseases. The gene was preliminarily tested for type I diabetes via genome-wide association study (GWAS) ([@bib5]), and this gene was later studied in various autoimmune diseases.

Some loci are involved in multiple autoimmune diseases, but the associated SNP and/or allele is not the same for each disease. For example, SNPs of TNFAIP3 region associated with systemic lupus erythematosus, rheumatoid arthritis, and type1 diabetes are different from SNPs associated with psoriasis and celiac disease ([@bib14]; [@bib19]; [@bib13]). Similarly, our study differed in conclusion with [@bib1], who studied CLEC16A SNPs in type 1 diabetes complicated with AITDs and concluded that CLEC16A SNPs are not significantly associated with AITDs alone in Japanese. The findings from our study indicate the association between CLEC16A variant rs6498169 and AITDs (*P* = 0.029) and HT (*P* = 0.018). This maybe attributed to the fact that the risk loci for type 1 diabetes might be different from that of AITD. Many studies suggest that not only different populations may bring different relationships of gene studies and diseases but variant regions also can contribute to the different distribution of gene polymorphisms. Differences in ethnicity could also have been the reason for the variation in our results, but similar to [@bib1], our study failed to demonstrate a significant association between rs2903692 and AITDs. These results still require confirmation by other large-scale studies to get a better understanding of the contribution of the CECL16A gene to AITD.

We also showed that the G allele of rs6498169 of CLEC16A increased susceptibility to HT by 34% that is the result when rs6498169 SNP, G, and A alleles were compared in patients with HT and controls, *P* = 0.018 and OR 1.34 (not shown in [Table 2](#t2){ref-type="table"}). According to the research done by [@bib10], there are some similarities in their conclusion where the G allele of rs6498169 has also showed increased in frequency in patients with multiple sclerosis. This finding indicates that many autoimmune diseases might share similar loci. Unfortunately, the genotype GG in rs6498169 only showed a marginally significant trend in HT.

Analyzing the correlation of the clinical subphenotypes and the alleles, none of the comparisons (cases with each clinical phenotype *vs.* those without) showed any statistical significance, likely because of the insufficient statistical power caused by the limited sample size after stratification. C-type lectin domain structure, which is expressed by dendritic cells, is crucial for tailoring immune responses to pathogens. Our results may add to the understanding of mechanisms for the genetic risk to AITDs as it is the complex disease with multifactorial pathophysiological mechanisms. As for now we don't know the exact biological mechanism as to why CLEC16A gene is associated with HT and not GD, but possibly it reflects the different underlying pathogenic mechanisms of the two diseases. Whole-genome linkage studies on multiple families with AITDs have shown that multiple genes are responsible for a predisposition towards GD and HT and that some are common to both diseases and some are unique. Research on the exact mechanism of CLEC16A pathway on how it influences HT will be of interest to our future projects. It also should be noted that the lack of association of CLEC16A gene with GD in our study does not completely rule out CLEC16A as a candidate gene for GD. Studies with a larger sample size are required to further identify these SNPs carrying a smaller risk.

In conclusion, the CLEC16A gene is a newly discovered AITDs susceptibility gene. As interesting as the results are, still the G allele of CLEC16A is not explaining much about AITDs or HT. If these results are confirmed in other ethnic groups, they may help us understand something about the genetics of HT. Further effort is needed to understand the functional properties of CLEC16A, and more loci should be studied to uncover its association with AITDs.
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